Cargando…
The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373007/ https://www.ncbi.nlm.nih.gov/pubmed/34949112 http://dx.doi.org/10.18553/jmcp.2022.28.1.119 |
_version_ | 1785078473425944576 |
---|---|
author | Tice, Jeffrey A Touchette, Daniel R Lien, Pei-Wen Agboola, Foluso Nikitin, Dmitriy Pearson, Steven D |
author_facet | Tice, Jeffrey A Touchette, Daniel R Lien, Pei-Wen Agboola, Foluso Nikitin, Dmitriy Pearson, Steven D |
author_sort | Tice, Jeffrey A |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-10373007 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Academy of Managed Care Pharmacy |
record_format | MEDLINE/PubMed |
spelling | pubmed-103730072023-07-31 The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council Tice, Jeffrey A Touchette, Daniel R Lien, Pei-Wen Agboola, Foluso Nikitin, Dmitriy Pearson, Steven D J Manag Care Spec Pharm Perspectives on Value Academy of Managed Care Pharmacy 2022-01 /pmc/articles/PMC10373007/ /pubmed/34949112 http://dx.doi.org/10.18553/jmcp.2022.28.1.119 Text en Copyright © 2022, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Perspectives on Value Tice, Jeffrey A Touchette, Daniel R Lien, Pei-Wen Agboola, Foluso Nikitin, Dmitriy Pearson, Steven D The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council |
title | The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council |
title_full | The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council |
title_fullStr | The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council |
title_full_unstemmed | The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council |
title_short | The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council |
title_sort | effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: a summary from the institute for clinical and economic review’s new england comparative effectiveness public advisory council |
topic | Perspectives on Value |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373007/ https://www.ncbi.nlm.nih.gov/pubmed/34949112 http://dx.doi.org/10.18553/jmcp.2022.28.1.119 |
work_keys_str_mv | AT ticejeffreya theeffectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT touchettedanielr theeffectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT lienpeiwen theeffectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT agboolafoluso theeffectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT nikitindmitriy theeffectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT pearsonstevend theeffectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT ticejeffreya effectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT touchettedanielr effectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT lienpeiwen effectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT agboolafoluso effectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT nikitindmitriy effectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT pearsonstevend effectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil |